
    
      Approximately one third of patients treated for localized breast cancer will present a
      metastatic evolution and 5% of patients are metastatic immediately.

      At this stage, the malignancy is incurable with a median survival from 2 to 3 years.

      Metastatic breast cancer treatment is part of a multidisciplinary approach. These two
      objectives are to prolong survival and improve quality of life. At present, there is no
      standard after the first line of chemotherapy, with fe strategy studies Eribulin is now a new
      therapeutic option to consider. Many patients have benefited from this treatment option and
      it seems interesting to evaluate in real life the effecacy and tolerance of chemotherapy.
    
  